The Prevalence of HIV-Drug Resistance with HIV Mutation Incidence

Abstract

Treatment of HIV / AIDS patients with antiretroviral treatment is necessary for HIV/AIDS program. The

goal is to lower the amount of virus in the blood as possible. The problem of HIV treatment is mutation and drug resistance. The resistance caused by the change of genetic diseases. The resistance data used to alternative treatment plan better. This study aims to Study the incidence of mutation of the virus in treated patients with antiretroviral.The16,875 sampleswereHIV Viral load testing OPDC9 lab during between January 2008 to December 2012, when result more than 2,000 copies/ml, they were testing by HIV genotype drug resistance. The HIV genome virus can detectable in 3,428 samples, and get to HIV drug resistance testingin 885 samples. Mean of viral load was 4.5 log10.The prevalence of antiretroviral adherence average 18.5% increase by about 3 percent per year. The NRTIs and NNRTIs groups are mainly resistance groups of antiretroviral, it represent in 59.2%, and no evidence of resistance result were 18.9%. The most of resistance mutation point ar eM184V 589 (66.6%), Y181C 379 (42.8%), G190A 231 (26.1%), D67N 191 (21.6%) and T215F 186 (21.0%).The Nevirapineresistance (NVP) is the most resistance and minor is Lamivudine (3TC) and Efavirenz (EFV).The prevalence of HIV drug resistancesamplesare 42.5 per thousand populations. Incidence of new HIV drug resistance in the sample is detected viral load after antiretroviral drugs to 2.9 per year. Results of this study can be used as basic data for decision of health providers. In particular, the factors that affect the drug are not consistency medication and loss follows up case.